JP2023527354A5 - - Google Patents

Info

Publication number
JP2023527354A5
JP2023527354A5 JP2022572560A JP2022572560A JP2023527354A5 JP 2023527354 A5 JP2023527354 A5 JP 2023527354A5 JP 2022572560 A JP2022572560 A JP 2022572560A JP 2022572560 A JP2022572560 A JP 2022572560A JP 2023527354 A5 JP2023527354 A5 JP 2023527354A5
Authority
JP
Japan
Prior art keywords
aav
manipulated
item
guide rna
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527354A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034323 external-priority patent/WO2021242903A2/en
Publication of JP2023527354A publication Critical patent/JP2023527354A/ja
Publication of JP2023527354A5 publication Critical patent/JP2023527354A5/ja
Pending legal-status Critical Current

Links

JP2022572560A 2020-05-26 2021-05-26 標的rnaを修飾するための組成物及び方法 Pending JP2023527354A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063030166P 2020-05-26 2020-05-26
US63/030,166 2020-05-26
US202063112329P 2020-11-11 2020-11-11
US63/112,329 2020-11-11
US202063119921P 2020-12-01 2020-12-01
US63/119,921 2020-12-01
US202163153175P 2021-02-24 2021-02-24
US63/153,175 2021-02-24
US202163178059P 2021-04-22 2021-04-22
US63/178,059 2021-04-22
PCT/US2021/034323 WO2021242903A2 (en) 2020-05-26 2021-05-26 Compositions and methods for modifying target rnas

Publications (2)

Publication Number Publication Date
JP2023527354A JP2023527354A (ja) 2023-06-28
JP2023527354A5 true JP2023527354A5 (cg-RX-API-DMAC7.html) 2024-06-03

Family

ID=76502872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572560A Pending JP2023527354A (ja) 2020-05-26 2021-05-26 標的rnaを修飾するための組成物及び方法

Country Status (6)

Country Link
US (1) US20230193279A1 (cg-RX-API-DMAC7.html)
EP (1) EP4158024A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023527354A (cg-RX-API-DMAC7.html)
AU (1) AU2021280283A1 (cg-RX-API-DMAC7.html)
CA (1) CA3177380A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021242903A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
US20240279656A1 (en) * 2021-06-29 2024-08-22 Shape Therapeutics Inc. Engineered Guide RNAs and Polynucleotides
EP4363579A1 (en) * 2021-06-29 2024-05-08 Shape Therapeutics Inc. Engineered guide rnas and polynucleotides
JP2024533163A (ja) 2021-09-03 2024-09-12 タシト・セラピューティクス・インコーポレーテッド スプライソソーム構成要素のリクルートを介したrna編集
JP2024542983A (ja) * 2021-10-26 2024-11-19 シェイプ セラピューティクス インコーポレイテッド Rna編集組成物及び使用方法
JP2024543208A (ja) * 2021-12-01 2024-11-19 シェイプ セラピューティクス インコーポレイテッド Lrrk2を標的としたrna編集のための遺伝子操作されたガイドrna及びポリヌクレオチド
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (ko) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
WO2024137991A2 (en) * 2022-12-23 2024-06-27 Shape Therapeutics Inc. Engineered guide rnas and polynucleotides
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
JP2026510408A (ja) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 神経障害の処置のためのアンチセンスオリゴヌクレオチド
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024197951A1 (zh) * 2023-03-31 2024-10-03 时夕(广州)生物科技有限公司 一种与rna编辑靶位点形成编辑底物的序列
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
EP4774393A1 (en) 2023-09-07 2026-07-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of metabolic disorders
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
TW202523678A (zh) * 2023-12-14 2025-06-16 國立臺灣大學 CRISPRI標靶α-突觸核蛋白
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
GB202405143D0 (en) 2024-04-11 2024-05-29 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of poly-q disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
WO2026136663A1 (en) 2024-12-18 2026-06-25 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015367378A1 (en) * 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
US10370667B2 (en) * 2015-11-18 2019-08-06 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
US11274300B2 (en) * 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
KR102678809B1 (ko) * 2017-05-18 2024-06-26 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
WO2019084062A1 (en) * 2017-10-23 2019-05-02 The Broad Institute, Inc. SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION

Similar Documents

Publication Publication Date Title
JP7860169B2 (ja) 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
US20230203483A1 (en) Compositions and Methods Using SNRNA Components
JP2025148448A (ja) アデノ随伴ウイルスベクター変種
JP2023504314A5 (cg-RX-API-DMAC7.html)
CA3177380A1 (en) Compositions and methods for modifying target rnas
EP4476241A1 (en) Aav capsid variants and uses thereof
GB2590880A (en) RNA and DNA base editing via engineered ADAR recruitment
CN112930395A (zh) 靶向rna的融合蛋白组合物和使用方法
CA3097857A1 (en) Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular rna
JP2013531471A5 (cg-RX-API-DMAC7.html)
WO2015157070A2 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
CN114480440A (zh) 靶向中枢神经系统的aav载体
CN111218447A (zh) 使用统治型gRNA的CRISPR相关方法和组合物
JP2021522836A5 (cg-RX-API-DMAC7.html)
US20220380798A1 (en) AAV Expression Cassette and AAV Vectors Comprising the Same
JP2023551873A (ja) Cagリピート病を処置するためのrna標的化組成物および方法
JP2025507958A (ja) 操作された核内低分子RNA(snRNA)を含む組成物および方法
US20220175960A1 (en) Fasl immunomodulatory gene therapy compositions and methods for use
WO2025038430A1 (en) Aav capsid variants and uses thereof
JP2022522166A5 (cg-RX-API-DMAC7.html)
JP2026082853A (ja) 調節核酸配列
JP2021534794A (ja) 変異型garsタンパク質の発現を阻害するための生成物および方法
JP2023541444A5 (cg-RX-API-DMAC7.html)
CN117320741A (zh) 用于治疗cag重复疾病的靶向rna的组合物和方法
JP2022508835A5 (cg-RX-API-DMAC7.html)